Dexcom Archives - Page 11 of 14 - Medical Design Sourcing

7 diabetes treatment innovations to look out for on World Diabetes Day

World Diabetes Day — Nov. 14 — centers around raising awareness for those with diabetes.

This year, that aim remains the same, and medical technology companies continue to look for ways to continue improving the management of the metabolic disease.

Some of those treatments involve insulin, which was discovered as a treatment for diabetes in 1922 and remains a vital part of the standard of care. World Diabetes Day falls on Nov. 14 because it is the birthday of Frederick Banting, one of the scientists involved in discovering insulin as a treatment for diabetes.

However, while many medtech companies look for ways to make insulin accessible and efficient in treating diabetes, others are innovating treatment avenues outside of insulin. Regardless of the path chosen, all have created intriguing options for managing and treating diabetes. Here are seven innovations in diabetes treatment that are worth keeping an eye on:

Next>>

7 diabetes treatment innovations to look out for on World Diabetes Day

World Diabetes Day — Nov. 14 — centers around raising awareness for those with diabetes.

This year, that aim remains the same, and medical technology companies continue to look for ways to continue improving the management of the metabolic disease.

Some of those treatments involve insulin, which was discovered as a treatment for diabetes in 1922 and remains a vital part of the standard of care. World Diabetes Day falls on Nov. 14 because it is the birthday of Frederick Banting, one of the scientists involved in discovering insulin as a treatment for diabetes.

However, while many medtech companies look for ways to make insulin accessible and efficient in treating diabetes, others are innovating treatment avenues outside of insulin. Regardless of the path chosen, all have created intriguing options for managing and treating diabetes. Here are seven innovations in diabetes treatment that are worth keeping an eye on:

Next>>

7 diabetes treatment innovations to look out for on World Diabetes Day

World Diabetes Day — Nov. 14 — centers around raising awareness for those who live every day with diabetes.

This year, that aim remains the same, and medical technology companies all over the world continue to look for ways to help manage the metabolic disease.

Some of those treatments involve insulin, which was discovered as a treatment for diabetes in 1922 and remains the standard of care. World Diabetes Day falls on Nov. 14 because it is the birthday of Frederick Banting, one of the scientists who helped to discover insulin as a treatment for diabetes.

However, while many medtech companies look for ways to make insulin accessible and efficient in treating diabetes, others are innovating treatment avenues outside of insulin. Regardless of the path chosen, all have created intriguing options for helping to manage and treat diabetes. Here are seven innovations in diabetes treatment that are worth keeping an eye on:

Next>>

Dexcom enlists celebrities to promote The Global Movement for Time in Range

Dexcom (NSDQ:DXCM) announced today that it will utilize some star power to boost The Global Movement for Time in Range.

Musician, actor and philanthropist Nick Jonas, along with musician, actress, author and entrepreneur Patti LaBelle will both use their platforms to promote the initiative.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom posts Street-beating Q3, raises guidance ahead of G7 launch

Dexcom (NYSE:DXCM) posted third-quarter financial results that topped Wall Street projections as it looks to launch its next-generation G7 system.

The San Diego-based diabetes management technology developer posted profits of $70.9 million, or 71¢ per share, on sales of $650.2 million for the three months ended Sept. 30, 2021, for a 1.8% bottom-line slide on sales growth of 29.8%.

Adjusted to exclude one-time items, earnings per share were 89¢, 26¢ ahead of Wall Street, where analysts were looking for sales of $617.8 million.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom announces Garmin as first partner for real-time APIs

[Image from Garmin]Dexcom (NYSE:DXCM) announced today that Garmin introduced its Dexcom Connect IQ apps on its smartwatch and cycling computer.

Garmin today launched the apps to provide people using the Dexcom G7 continuous glucose monitor (CGM) with Type 1 and Type 2 diabetes a way to quickly see glucose levels and trends, even while working out. Apps compatible with the Garmin smartwatch or cycling computer can be downloaded now from the Connect IQ store in the U.S.

Get the full story at our sister site, Drug Delivery Business News.

September 2021 Issue: Our latest Medical Device Handbook is out!

Making medical devices: Everything you need to know

The innovation-fueled evolution of drug eluting stents

Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’

Getting the inside scoop behind top medtech innovations

Autumn is upon us, and it is once again time to sip a pumpkin spice latte — or a pumpkin beer — and crack open our latest Medical Device Handbook.

Once again, we’ve reached out to experts across the industry to curate dozens of “what is” and “how to” types of articles that cover a breadth of categories: components, drug delivery, manufacturing and machining, materials, product design and development, regulatory, software, sterilization services and tubing.

As the years go by, I’m proud that we’re including more insights from the major medical device companies in each succeeding issue. This time around, we spoke to experts involved in some of the major industry innovations of the past decade:

Now VP of R&D …

MedTech 100 roundup: Industry climbs with earnings season in full swing

The medtech industry remains on the upswing as companies see their stocks rising with quarterly earnings providing a boost.

MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (July 30) at 118.86 points. Two weeks ago aside — when the index shot up to 145.88 points and quickly tumbled down — this mark would be the index’s all-time best.

The total at the end of last week represents a 2.9% rise from the 115.54-point tally posted by the index at the end of last week (July 23).

Medtech’s performance continues to reflect an overall rebound from the struggles brought on by the COVID-19 pandemic, too. The industry has registered a 28.7% increase from the pre-pandemic high of 92.32 (set on Feb. 19, 2020). Moreover, it remains well ahead of the mid-pandemic low of 62.13 (March 23, 2020) as well, totaling a 91.3% ascent above that point.

The industry’s performance had no cor…

Dexcom rises on Street-beating Q2, raised guidance

Dexcom (NSDQ:DXCM) shares ticked up after hours on second-quarter results that topped the consensus forecast.

The San Diego-based continuous glucose monitor developer posted profits of $62.9 million, or 63¢ per share, on sales of $595.1 million for the three months ended June 30, 2021, for a 35.9% bottom-line gain on sales growth of 31.7%.

Get the full story at our sister site, Drug Delivery Business News.

MedTech 100 roundup: Return to normal after last week’s spike

After rising more than 31 points to heights never before reached, the medtech industry returned to normal this past week.

MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (July 23) at 115.54 points, a total that, had it not been for last week, would be the index’s all-time high.

However, the index finished the previous week (July 16) at 145.88 points, a remarkable 27.1% rise week-over-week, registering by far the greatest increase the index has seen since its inception — and perhaps an anomaly. Although the index slid by -20.8%, it remains in a stronger position than ever before, last week notwithstanding.

Medtech’s performance continues to reflect an overall rebound from the struggles brought on by the COVID-19 pandemic, too. The industry has registered a 25.2% increase from the pre-pandemic high of 92.32 (set on Feb. 19, 2020). It remains well ahead of the mid-pandemic low…

Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’

As we enter what may be the “new normal,” Dexcom’s CEO bets the company can pave the way in continuous glucose monitoring.

Dexcom (NSDQ:DXCM), like any company seeking to innovate, remains in a state of perpetual forward motion.

That’s the way chair, president & CEO Kevin Sayer views it, anyway. As the company looks toward the future, the G7 continuous glucose monitor is the next big thing.

San Diego–based Dexcom’s latest iteration of its CGM system — building on the G6, which first won FDA approval in 2018 — has inspired plenty of optimism, both within the ranks of Dexcom and likely among customers, too.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’

As we enter what may be the “new normal,” Dexcom’s CEO bets the company can pave the way in continuous glucose monitoring.

Dexcom (NSDQ:DXCM), like any company seeking to innovate, remains in a state of perpetual forward motion.

That’s the way chair, president & CEO Kevin Sayer views it, anyway. As the company looks toward the future, the G7 continuous glucose monitor is the next big thing.

San Diego–based Dexcom’s latest iteration of its CGM system — building on the G6, which first won FDA approval in 2018 — has inspired plenty of optimism, both within the ranks of Dexcom and likely among customers, too.

Get the full story at our sister site, Drug Delivery Business News.